News

The neuroprotective efficacy of NK-102 is based on its dual mechanism of action. After a brain injury NK-102, firstly blocks neuronal apoptosis and also reduces inflammation by inhibiting

The updated product label, also called a package insert, includes bolded warnings and precautions that describe events that have been reported after Feraheme administration in the post-marketing environment,

In collaboration with Ark, the pre-clinical studies were partly funded by the Wellcome Trust, carried out by researchers at University College London (UCL) and the Rowett Institute of

Peginesatide is a novel investigational synthetic, PEGylated peptidic compound that binds to and activates the erythropoietin receptor and thus acts as an ESA. Affymax and Takeda are collaborating

Takeda Pharma said that Leuplin was approved for CPP treatment in 1994, with a maximum allowable dosage of 90µg/kg/4 weeks. The MHLW requested Takeda to modify Leuplin’s dosage

As per the terms of the agreement, IntelGenx has obtained worldwide rights to US Patent 7,592,328 and all corresponding foreign patents and patent applications to exclusively develop and

In the study, 25 asymptomatic HAE patients with a history of frequent attacks received once weekly administrations of 50 U/kg of Ruconest for 8 weeks. The study results

Pfizer and Protalix BioTherapeutics had entered into an agreement to develop and commercialise Taliglucerase alfa On 30 November 2009. Under the terms of the agreement, Pfizer received exclusive

Under the contract, Selcia’s chemists and biologists will continue to provide integrated drug discovery services to support Gilead‘s liver disease research programmes. Gilead Research senior vice president William